Myocarditis and Pericarditis due to COVID vaccine in individuals in Ontario, Canada, following COVID-19 shot; found higher rates of myocarditis or pericarditis associated with receipt of mRNA-1273...

...compared with BNT162b2 as a second dose, particularly among male individuals aged 18 to 24 years. Higher rates were also observed with shorter interdose intervals.

SOURCE:

Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada

“The findings of this population-based cohort study of Ontario adolescents and adults with myocarditis or pericarditis following mRNA COVID-19 vaccination suggest that vaccine products and interdose intervals, in addition to age and sex, may be associated with the risk of myocarditis or pericarditis after receipt of these vaccines. Vaccination program strategies, such as age-based product considerations and longer interdose intervals, may reduce the risk of myocarditis or pericarditis following receipt of mRNA vaccines.”